Ryuichi Kitamura
Overview
Explore the profile of Ryuichi Kitamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okamoto I, Yoshioka H, Takeda K, Satouchi M, Yamamoto N, Seto T, et al.
J Thorac Oncol
. 2011 Nov;
7(2):427-33.
PMID: 22071785
Introduction: TSU-68 is an oral small-molecule inhibitor that targets vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor β, and fibroblast growth factor receptor 1. An open-label, single-arm, phase...
2.
Hatano B, Goto M, Fukumoto H, Obara T, Maki T, Suzuki G, et al.
J Med Virol
. 2011 Feb;
83(4):568-73.
PMID: 21328369
The 2009 pandemic H1N1 influenza A virus spread quickly worldwide in 2009. Since most of the fatal cases were reported in developing countries, rapid and accurate diagnosis methods that are...
3.
Ajioka H, Morita F, Akizawa Y, Yoshida K, Kitamura R, Takimoto H
Nihon Yakurigaku Zasshi
. 2010 Aug;
136(2):113-20.
PMID: 20702972
No abstract available.
4.
Kitamura R, Matsuoka K, Nagayama S, Otagiri M
Drug Metab Pharmacokinet
. 2009 Jan;
23(6):421-7.
PMID: 19122336
The anti-angiogenic agent TSU-68 is known to rapidly induce cytochrome P450 activity responsible for its own hydroxylation in rats. In this study, we identified CYP1A1 and CYP1A2 as the TSU-68-induced...
5.
Kitamura R, Asanoma H, Nagayama S, Otagiri M
Drug Metab Dispos
. 2008 Mar;
36(6):1003-9.
PMID: 18322074
(Z)-5-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68) is a new anticancer drug that inhibits angiogenic receptor tyrosine kinases, which play a crucial role in tumor-induced vascularization. TSU-68 undergoes hepatic oxidation and glucuronidation. Incubation of...
6.
Kitamura R, Yamamoto Y, Nagayama S, Otagiri M
Drug Metab Dispos
. 2007 Jun;
35(9):1611-6.
PMID: 17567729
TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) is a new drug under investigation that inhibits receptor tyrosine kinases involved in tumor angiogenesis. In clinical pharmacokinetic studies, lower plasma concentrations of orally administered TSU-68 are...
7.
Kayali A, Flores L, Lopez A, Kutlu B, Baetge E, Kitamura R, et al.
Diabetes
. 2007 Mar;
56(3):703-8.
PMID: 17327439
Limited organ availability is an obstacle to the widespread use of islet transplantation in type 1 diabetic patients. To address this problem, many studies have explored methods for expanding functional...
8.
Matsuoka K, Kitamura R, Matsushima E, Kawaguchi Y
J Pharm Biomed Anal
. 2003 Feb;
31(1):47-55.
PMID: 12560048
A liquid chromatographic-electrospray ionization tandem mass spectrometric (LC-ESI/MS/MS) method was developed for the quantitative analysis of a novel anticancer drug, 3'-C-ethynylcytidine (I) in human plasma and urine. I and its...
9.
Kitamura R, Tanaka Y
Nihon Rinsho
. 2002 Oct;
60 Suppl 9:452-8.
PMID: 12387033
No abstract available.
10.
Nagase T, Murakami T, Tsukada T, Kitamura R, Chikatsu N, Takeo H, et al.
J Clin Endocrinol Metab
. 2002 Jun;
87(6):2681-7.
PMID: 12050233
To date about 20 activating mutations in the calcium-sensing receptor (CaR) gene have been identified to cause autosomal dominant hypocalcemia (ADH) or sporadic hypoparathyroidism. We report a novel activating mutation...